Dermo beta brachytherapy with 188-Re in squamous cell carcinoma of the penis: a new therapy

Carrozzo, Anna Maria; Sedda, Antioco Franco; Muscardin, Luca; Donati, Pietro; Cipriani, C.

doi:10.1684/ejd.2013.1927

Cited by 16 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different to iridium-192, rhenium-188 has a flatter dose distribution in depth providing thus a more homogeneous dose to the tumor. The rapid drop of dose after 3 mm spares underlaying layers of tissue, of particular importance for mucous tissues like lips and genitals (5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study

Cipriani¹,

DeSantis²,

Dahlhoff³

et al. 2020

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

Objectives: This study aimed to provide long-term clinical data about an innovative epidermal radioisotope therapy called Rhenium-SCT V R (Skin Cancer Therapy) for non-melanoma skin cancer (NMSC), based on the use of the non-sealed beta emitter rhenium-188. Material and methods: 52 NMSC patients with a mean age of 71.7 years were treated with rhenium-188 skin cancer therapy between the years 2005 and 2014. An acryl matrix containing rhenium-188 was applied on a plastic foil covering the tumor. The treatment time for reaching a radiation dose of 50 Gy was calculated by a software program. Patients' characteristics and clinical follow-up data were collected and retrospectively analyzed. Results: Overall 55 lesions (32 BCC, 19 SCC, 2 M. Bowen and 2 extramammary Paget's disease (EMPD)) mainly in the head and neck region (72.3%) were treated. The average size of the irradiation area was 9.79 cm 2 and the mean treatment time 46.35 min. All lesions showed a complete remission after a follow-up period between 3 and more than 12 months. No complications or other post-interventional problems were reported. Conclusions: Rhenium-SCT V R is considered as an effective, rapid, safe, painless treatment mostly performed in a single therapeutic session, regardless of the shape complexity, anatomical site and number of lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study

Cipriani¹,

DeSantis²,

Dahlhoff³

et al. 2020

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…This 188 Re-cream can be deposited through a CE-labeled applicator (Figure 10), now commercially available under tradename Rhenium-SCT® (Skin Cancer Therapy), from OncoBeta® GmbH (Garching, Germany) and this system is routinely used in Italy and South-Africa, where it is an approved therapy for the treatment of BCC and SCC, including Bowen's disease, in patients with comorbidities, when surgical intervention is not possible or conventional therapies cannot be expected to provide a satisfactory cosmetic result due to the anatomical location. This treatment modality is particularly interesting when surgery is not desirable, as in the case of SCC of the penis (226). In that study, 15 patients, ranging in age from 31 to 92 years, were treated with the Re-SCT® brachytherapy kit.…”

Section: Re Particulatesmentioning

confidence: 99%

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

et al. 2019

View full text Add to dashboard Cite

Rhenium-188 ( 188 Re) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-life, which has been shown to be a very attractive candidate for use in therapeutic nuclear medicine. The high beta emission has an average energy of 784 keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is efficient for imaging and for dosimetric calculations. These key characteristics identify 188 Re as an important therapeutic radioisotope for routine clinical use. Moreover, the highly reproducible on-demand availability of 188 Re from the 188 W/ 188 Re generator system is an important feature and permits installation in hospital-based or central radiopharmacies for cost-effective availability of no-carrier-added (NCA) 188 Re. Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent a “theranostic pair.” Thus, preparation and targeting of 188 Re agents for therapy is similar to imaging agents prepared with 99m Tc, the most commonly used diagnostic radionuclide. Over the last three decades, radiopharmaceuticals based on 188 Re-labeled small molecules, including peptides, antibodies, Lipiodol and particulates have been reported. The successful application of these 188 Re-labeled therapeutic radiopharmaceuticals has been reported in multiple early phase clinical trials for the management of various primary tumors, bone metastasis, rheumatoid arthritis, and endocoronary interventions. This article reviews the use of 188 Re-radiopharmaceuticals which have been investigated in patients for cancer treatment, demonstrating that 188 Re represents a cost effective alternative for routine clinical use in comparison to more expensive and/or less readily available therapeutic radioisotopes.

show abstract

“…Because of anatomical locations which may be difficult to adequately reconstruct following surgical removal of basal cell and squamous cell carcinomas of the face and neck, the clinical use of locally applied beta-emitting radioisotopes thus offered an innovative alternative simple and inexpensive strategy [205][206][207][208][209][210], and This approach is based on use of a 188 Reimpregnated cream for topical application which had initially been commercially developed as the "ITM Rhenium-SCT™" (Skin Cancer Therapy) which was initially available from the ITG portfolio. Results of reported studies have demonstrated this to be an excellent approach for treatment of non-melanoma skin cancers and the results of several clinical studies have been published [206][207][208][209]. An important advantage of this strategy is that application of the cream automatically matches the skin conformity and does require pre-preparation of a radioactive applicator to match the anatomy of the therapy site.…”

Section: Use Of Homogeneously 188mentioning

confidence: 99%

“…Available literature from the OncoBeta company report that 188 Re treatment of over 700 patients with BCC and SCC resulted in an overall 85% success rate. One recent published study enrolled 53 patients who presented with histologically confirmed basal cell (BCC) and squamous cell (SCC) carcinoma [205][206][207][208]. Almost all patients undergoing treatment have had Dispensing tube for the OncoBeta ® applicator device filled with the 188 Re-labeled cream which is fitted into the dispenser unit sown in Figure 7.…”

Section: Use Of Homogeneously 188mentioning

confidence: 99%

Important Clinical Applications of 188Rhenium for Radionuclide Therapy

Shinto¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

Although established clinical utility is of key importance in choosing agents for radionuclide therapy, other key factors include costs and GMP availability of sterile, pyrogen-free, regulatory approved radiopharmaceuticals. No-carrieradded (NCA) 188 Rhenium(188 Re, 16.9 hour half-life; 155 keV gamma emission) is available on demand as 188 Reperrhenate from saline elution of a 188 Tungsten/ 188 Rhenium(188 W/ 188 Re) generator. The availability and superb radionuclidic and chemical properties make 188 Re an excellent candidate for radionuclide therapy. This radioisotope is readily attached to a variety of targeting agents and also emits high energy beta particles (Emax 2.12 MeV) for therapy. Over the last 30 years the effectiveness of 188 Re for a variety of therapeutic applications has been established in multiple clinical studies. This overview provides a brief summary of clinical applications with 188 Re-labeled agents as an introduction to the detailed clinical discussions in the following papers. Although 188 Re-labeled radiopharmaceuticals for routine clinical use and accompanying reimbursement are not yet commercially available, several agents have been evaluated in clinical studies. In addition, a large number of 188 Re radiopharmaceutical agents have been developed and evaluated in pre-clinical studies over the last three decades. This review focuses on providing examples of 188 Re-labeled radiopharmaceutical agents which have entered late stage clinical use and have demonstrated good efficacy. These key applications include palliative treatment of skeletal metastases, intra-arterial therapy of liver cancer and post PTCA intravascular inhibition of arterial restenosis. Also, 188 Re radiopharmaceuticals had been developed and initially assessed for synovectomy and for marrow suppression. More recently, a unique device-based technology has entered clinical use for therapy of non-melanoma skin cancer using a 188 Re topical cream. Finally, 188 Re-antibodies are being developed for the potential therapy of infectious disease and this unique new therapeutic strategy is expected to enter clinical trials in the near future.

show abstract

Dermo beta brachytherapy with 188-Re in squamous cell carcinoma of the penis: a new therapy

Cited by 16 publications

References 0 publications

Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study

Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

Important Clinical Applications of 188Rhenium for Radionuclide Therapy

Contact Info

Product

Resources

About